2025年欧洲肺癌大会（ELCC）期间，意大利IEO欧洲肿瘤研究所IRCCS专家Antonio Passaro教授在争议专场就“目前是否应将TKI联合疗法作为EGFR突变型非小细胞肺癌（NSCLC）一线标准治疗”这一前沿议题展开深度探讨。会后，Antonio Passaro教授应本刊特别邀请，针对本届大会的热点研究成果进行了独家解读。

Dr.Passaro：在本届ELCC大会上，MARIPOSA试验的最终总生存期（OS）公布。该试验对比了埃万妥单抗/兰泽替尼vs.奥希替尼单药用于EGFR经典突变晚期NSCLC患者一线治疗的疗效和安全性，这是首个与奥希替尼相比OS显著改善的随机III期试验。MARIPOSA研究数据令人瞩目，支持在EGFR突变晚期NSCLC一线治疗中优先考虑埃万妥单抗/兰泽替尼联合治疗，不仅针对具有高风险特征患者，也适用于其他患者群体。联合疗法的出现为EGFR突变患者开启了新时代。

 

Dr.Passaro:During this ELCC，the final overall survival data from the MARIPOSA trial will be presented.The trial combination of amivantamab/lazertinib versus osimertinib alone was the first randomized phase III trial versus osimertinib to confirm the significant improvement in overall survival.The data that will be discussed this afternoon by Professor Yang are very impressive and confirm the need to try to prioritize combination therapy in the first-line setting，not only in patients with high-risk features，but for other patients as well.The emergence of combination therapy is opening a new era for patients with EGFR alterations.

 

Dr.Passaro：毫无疑问是MARIPOSA研究（摘要4O）。MARIPOSA试验将为EGFR经典突变（Ex19del或L858R）晚期NSCLC患者的一线治疗开启新纪元。MARIPOSA研究数据与其他一线联合研究结果共同表明，毒性显著降低将是取得成功的关键因素。

 

Dr.Passaro:Of course，the MARIPOSA study.The MARIPOSA trial will open up a new era for patients with non-small cell lung cancer，particularly with EGFR mutations.The MARIPOSA data combined with other results confirm the significant reduction in toxicity which will be key for success in this particular setting.

 

Dr.Passaro：我们在2025 ELCC披露了埃万妥单抗用于EGFR外显子20插入突变（ex20ins）NSCLC患者的事后分析。这是埃万妥单抗在化疗经治ex20ins NSCLC患者中的首个真实世界数据，在真实临床治疗环境印证了CHRYSALIS试验结果。这项分析结果证实了埃万妥单抗治疗此类患者的效果，且临床治疗的安全性可管理。

 

Dr.Passaro:Here，we have reported the data from our post-hoc analysis using amivantamab in patients with exon 20 mutations.This is the first real-world data for amivantamab in patients with exon 20 after chemotherapy that confirm the data from the CHRYSALIS trial in a real-world setting.This data confirmed the use of amivantamab in this setting with a safety profile able to be managed in a clinical setting.

 

参考文献：

 

1.Amivantamab Plus Lazertinib vs Osimertinib in First-line(1L)EGFR-mutant(EGFRm)Advanced NSCLC:Final Overall Survival(OS)from the Phase 3 MARIPOSA Study.2025 ELCC，abstract 4O.

 

2.Passaro A，et al.Amivantamab monotherapy in patients with pre-treated NSCLC with EGFR Exon 20 Insertion Mutations:Real-World Data on efficacy and safety from the Italian biomarker ATLAS database.2025 ELCC，abstract 70P.

 

《肿瘤瞭望》在ELCC现场报道